390
Views
21
CrossRef citations to date
0
Altmetric
Review

Food allergy and anaphylaxis

, , &
Pages 111-120 | Published online: 20 Jun 2018

Abstract

Anaphylaxis is a severe and potentially life-threatening allergic reaction. There are numerous potential causes, with food allergy being the leading cause in children and the focus of this review. Most reactions involve an IgE-mediated mechanism, although non-IgE-mediated and nonimmunologic reactions can occur. Various cofactors to be discussed can place certain individuals at an increased risk of severe or fatal anaphylaxis. The clinical manifestations of anaphylaxis are broad and may involve multiple body systems. Diagnosis of food-related anaphylaxis is primarily based on signs and symptoms and supported, wherever possible, by identification and confirmation of a culprit food allergen. First-line treatment of anaphylaxis is intramuscular administration of epinephrine. Long-term management is generally focused on strict allergen avoidance and more recently on food desensitization using immunotherapy. This review provides an overview of anaphylaxis with a specific focus on food allergy.

Introduction

Anaphylaxis is defined as a serious allergic reaction that is rapid in onset and may cause death.Citation1 Although human studies of the immunologic mechanisms of anaphylaxis are limited, most cases involve the interaction between an allergen and allergen-specific IgE bound to high-affinity IgE receptors on mast cells and basophils. The most common causes of IgE-dependent reactions include food, medications, Hymenoptera venom, and latex rubber.Citation2

Although less common, anaphylaxis can also involve non-IgE-mediated mechanisms, including IgG- and complement-mediated reactions, and direct mast cell and basophil activation in the absence of immunoglobulins. Potential causes include physical factors, such as exercise, cold and heat, and iatrogenic agents, including radiocontrast media and opiates. Regardless of the underlying mechanism or trigger, ultimately, there is activation of a signaling cascade resulting in mast cell and basophil degranulation. These cells release multiple mediators including histamine, tryptase, leukotrienes and prostaglandins, which lead to the clinical manifestations of anaphylaxis. Cytokines important in allergic disease, including TNF-α, IL-4, IL-5, IL-6, IL-10, and IL-13, activate complement and the kallikrein–kinin systems, further contributing to symptoms. Platelet-activating factor (PAF) and nitric oxide also appear to play a role. PAF is released during allergic reactions, and decreased activity of PAF acetylhydrolase, the enzyme that degrades PAF, has been associated with more severe anaphylaxis.Citation2 Non-IgE-mediated reactions are clinically indistinguishable and have similar acute management despite their underlying mechanism.Citation3 The objective of this paper is to review recently published evidence related to food allergy/anaphylaxis addressing prevalence, diagnostics, and treatment, including primary prevention and immunotherapy, in the past year (January 1, 2017, to January 4, 2018).

Methods

A database search (Ovid MEDLINE® Epub Ahead of Print, In-Process & Other Non-Indexed Citations, Ovid MEDLINE® Daily, Ovid MEDLINE, and Versions(R) for articles, between January 1, 2017, and January 4, 2018) was conducted using the following key words: “anaphylaxis”, AND-ed “food allergy”.

Eligibility criteria

The following eligibility criteria were used for article inclusion: population: patients with food allergy and/or at risk for anaphylaxis; intervention: any approaches or protocols that incorporated a strategy for food allergy and anaphylaxis management; comparator: any studies irrespective of whether there was a comparator included in the study design; outcomes: any related to prevalence, diagnostics, and treatments including primary prevention and immunotherapy; and study design: experimental studies (e.g., randomized controlled trials [RCTs]), other experimental designs (e.g., non-randomized methods of assignment, controlled before–after studies, and interrupted time series), and observational studies (e.g., prospective or retrospective cohort, cross-sectional, and case–control). We excluded case reports, opinion-based reports (i.e., editorials, letters, and non-systematic or narrative reviews), and basic science or animal (nonhuman) studies.

Data synthesis

The analysis involved summarizing the data and presenting the results in a narrative synthesis. We prepared descriptive tables to give an overview of the included study characteristics. This manuscript was not designed to perform quantitative analysis, meta-analysis, or assessment of risk of bias.

Of 304 potentially relevant articles, a total of 15 articles with new insights on food allergy/anaphylaxis were selected. The majority of the studies () consisted of retrospective studies (n=7), population-based cohort studies (n=2), clinical trials (n=3), cross-sectional surveys (n=1), prospective studies (n=1), and retrospective chart review (n=1).

Table 1 Summary of included studies

The studies in the following overview address new insights on food allergy/anaphylaxis addressing prevalence, diagnostics, acute management, as well as primary prevention and immunotherapy (oral, epicutaneous, and sublingual routes).

Prevalence and characterization of food allergy/anaphylaxis

Increasing prevalence of anaphylaxis is supported by a recent US study conducted between January 1, 2001, and December 31, 2010, which examined records of 2,386 Olmsted County, MN, residents with a diagnosis of anaphylactic shock or related diagnoses (e.g., venom-related toxic events, medication reactions). A total of 631 cases that fit the clinical criteria of anaphylaxis were identified (median age 31 years). The overall incidence of anaphylaxis was 42/100,000 person-years. There was an increase in the overall incidence of anaphylaxis during the study period, with an average increase of 4.3%/year (P<0.001). A 9.8%/year increase in the incidence of food-related anaphylaxis was also noted.Citation4

Previous studies have reported food as the most common cause of anaphylaxis, which account for 30% of fatalities.Citation5 Our review included a recent retrospective study of 4,777 electronic records (July 2002 to October 2013), which revealed that 730 (15%) patients evaluated in the Allergy and Immunology Department of Cleveland Clinic (median age 34 years; 73% adults, 59% females, 87% Caucasians) met the World Health Organization (WHO) definition of anaphylaxis. The top three causes were food (29.9%), venom (26.4%), and medications (13.3%), with venom being the most common in adults.Citation6 In children, the most common foods were peanuts (32.0%), tree nuts (22.7%), milk (17.2%), and eggs (16.4%) as compared to adults where the most common foods were shellfish (34.4%), tree nuts (20.0%), and peanuts (12.2%).Citation6

In addition, a Canadian study (between April 2011 and February 2014) prospectively examined recurrence rates of anaphylaxis among 292 children (mean age 6.5 years) who attended an emergency department with anaphylaxis (two tertiary care pediatric hospitals and a third general hospital). The study reported an annual recurrence rate of 17.6% with food being the most common cause of these recurrences (84.6%).Citation10

A Canadian survey of self-reported food allergy showed an estimated food allergy prevalence of 6.9% in children (1–17 years) and 7.7% in adults (18+ years).Citation7 Approximately 1.1% of respondents were allergic to peanut (PN). These estimates are higher than a recent electronic health record (Partners HealthCare, Boston, MA, USA) review that reported a 3.6% prevalence of food allergy (97,482 of 2,714,851 patients).Citation8

Allergic comorbid diseases have also been examined and are more prevalent in food allergic individuals. A US registry of PN allergic children (The Riley PN Registry), which reported the 5-year experience of 1,070 children (mean age 1 year), showed coexistent atopic dermatitis (65%), asthma (41%), and additional food allergies (68.7%).Citation9

Risk factors for anaphylaxis

Although our review did not capture recent studies examining this question, previous studiesCitation3,Citation11Citation13 have shown that patient factors can increase the risk of severe or fatal anaphylaxis.

Examples of age-related factors include anaphylaxis in infancy, which is difficult to recognize as they cannot describe their symptoms, and risk-taking behaviors in teens and young adults including failure to avoid known triggers and carry an epinephrine autoinjector (EAI). In adults, chronic diseases such as asthma and cardiovascular diseases and their treatments with beta-blockers and angiotensin-converting enzyme inhibitors place them at an increased risk.Citation3 Beta-blockers can increase reaction severity and specifically can make anaphylaxis more difficult to treat.Citation3

Mast cell disorders, including mastocytosis, and severe atopic diseases, including allergic rhinitis, can also increase the risk of severe or fatal anaphylaxis. Cofactors (external circumstances associated with more severe allergic symptoms) such as exercise, alcohol, nonsteroidal anti-inflammatory drugs (NSAIDs), acute infection, stress, and perimenstrual status can decrease allergen thresholds and amplify an anaphylactic reaction.Citation11,Citation12

Factors that have been associated with fatality with regard to food-induced anaphylaxis include reactions to PN and tree nut (TN), delayed administration of epinephrine, a previous history of food allergy, asthma especially if poorly controlled, and age (more frequent in teenagers and young adults).Citation13

Diagnosis and clinical manifestations

The definition of anaphylaxis is based on an expert consensus and was published in 2006. Anaphylaxis is highly likely when any one of these three criteria are fulfilled: 1) sudden onset of an illness, with involvement of the skin, mucosal tissue, or both and at least one of respiratory compromise or reduced blood pressure or associated symptoms of end-organ dysfunction; 2) two or more of the following that occur rapidly after exposure to a likely allergen: skin/mucosal involvement, respiratory compromise, reduced blood pressure, or gastrointestinal (GI) symptoms; and 3) reduced blood pressure after exposure to a known allergen.Citation3

Cutaneous manifestations are reported in 80%–90% of all patients. In the Riley PN Registry, most reactions involved the skin (55%).Citation9 In the absence of skin symptoms, anaphylaxis may be difficult to recognize and can occur in up to 20% of patients, specifically food or venom allergy.Citation1,Citation3 Anaphylaxis can range in severity from mild symptoms to very severe reactions, progressing within minutes to respiratory compromise or cardiovascular collapse and death. It is important to recognize that the clinical manifestations and severity of reactions are unpredictable and may differ from one patient to another and from one episode to another in the same patient.Citation3

Biphasic reactions can also occur, where patients experience a recurrence of symptoms within 72 hours of the initial anaphylactic event without re-exposure to the trigger. In a meta-analysis by Lee et al,Citation14 the reported rate of biphasic reactions among the included studies was 4.6%. They noted that the risk of a biphasic reaction was greater with hypotension on presentation and an unknown inciting trigger. In general, it is recommended that all patients be observed for at least 4–6 hours after an anaphylactic reaction; however, this should be individually tailored.Citation14

Diagnostics

Laboratory studies may help establish a diagnosis of anaphylaxis. Increased levels of serum total tryptase and plasma histamine can be observed during or shortly after an acute anaphylactic episode. Tryptase levels peak 60–90 minutes after the onset of symptoms and remain elevated for at least 5 hours, whereas plasma histamine remains elevated for only 30–60 minutes.Citation15 Normal levels do not rule out anaphylaxis and are usually present in patients with anaphylaxis to food and in those who are normotensive.Citation16

Skin prick tests (SPTs)

To identify a potential trigger (e.g., food, medications, insect stings), SPT is a reliable method.Citation17 With regard to food allergy, a positive SPT has a sensitivity of ~90% and a specificity of ~50%. An SPT alone is not sufficient for diagnosis and must be interpreted in the context of the clinical history. The negative predictive value (NPV) of SPT is >95%, and a negative result essentially confirms the absence of IgE-mediated allergic reactivity.Citation13

Serum-specific IgE

A serum-specific IgE can be a useful alternative if an SPT cannot be performed or is unavailable. The ImmunoCAP method uses a fluorescent enzyme immunoassay to detect selective specific IgE antibodies. This is in contrast to Immuno Solid-phase Allergen Chip (ISAC) that measures specific IgE antibodies against multiple allergen components in a single assay.Citation18 Higher concentrations of food-specific IgE levels correlate with an increasing likelihood of a clinical reaction but do not correlate well with reaction severity. In food-sensitized patients, specific IgE levels with >95% predictive risk values of a positive (failed) food challenge have been identified. The 95% positive predictive value (PPV) calculations depend on the population sampled and vary with specific prevalence rates in different geographic regions; hence, they are not completely generalizable. These levels are established for cow’s milk (CM) (≥15 kU/L), egg (≥7 kU/L), PN (≥14 kU/L), TN (≥15 kU/L), and fish (≥20 kU/L).Citation13

Our review yielded a retrospective study of 2,068 new patient (69% female) referrals between April 4, 2011, and March 31, 2014, at the University Hospital of Wales, which revealed that in patients with nut allergy, the detection rates of SPT (56%) and ISAC (65%) were lower than those of ImmunoCAP (71%). In addition, ISAC had a higher detection rate (88%) than ImmunoCAP (69%) or SPT (33%) for the diagnosis of oral allergy syndrome (OAS). The higher detection rate of OAS was explained as being due to the lack of availability of component-resolved diagnostics (CRDs) in SPT, in particular pathogenesis-related (PR)-10. In this population, they concluded that although ImmunoCAP, ISAC, and SPT performed similarly for confirmation of food allergy and anaphylaxis, the ISAC was the most useful for confirmation of OAS.Citation18

CRD testing

CRD testing may predict the risk or severity of allergic reactions to specific food by measuring IgE to specific components and epitopes within an allergen source.Citation19 PN component testing studies have shown that positive testing to the peanut component Ara h2 is more sensitive and specific than IgE to whole PN and the most consistent marker for predicting PN allergy. Serum IgE to Ara h2 has 60%–100% sensitivity and 60%–90% specificity in predicting reactivity.Citation20 CRD testing can also identify cross-reactive specific components to other similar allergens from different pollen species or food items. For example, the PN component Ara h8 is positive in patients experiencing OAS.Citation21

Oral food challenges (OFCs)

If diagnostic tests remain unclear, an OFC may be considered for a suspected food and involves gradual feeding of the food to assess clinical reactivity.Citation13 Although uncommon, recent studies report the rate of anaphylaxis during OFC to range from 2% to 3%.Citation22,Citation23 A Japanese retrospective study evaluated 393 patients (median age 8.3 years; ≥5 years old), defined as of high risk of a severe reaction [anaphylactic history or antigen-specific IgE (>30 kU/L) to egg, milk, wheat, or peanut], and observed anaphylaxis (WHO definition) in 48% of cases during in-hospital OFC. Risk factors that were associated with severe symptoms were a history of a previous anaphylactic reaction and older age.Citation24 This underscores the recommendation that OFCs must be conducted cautiously by trained health care providers, where resuscitation equipment is available, and anaphylaxis can be appropriately managed.Citation19

Acute management

Acute management of an IgE-mediated anaphylactic reaction starts with rapid assessment of airway, breathing, and circulation. First-line treatment is epinephrine administered intramuscularly into the lateral thigh.Citation25 Treatment should be provided even if the diagnosis is uncertain since there are no absolute contraindications to the use of epinephrine.

The dose of epinephrine for the acute treatment of anaphylaxis is 0.01 mg/kg up to a maximum of 0.5 mg every 5–20 minutes as necessary. Glucagon should be considered in patients on beta-blockers.Citation15 All individuals receiving emergency epinephrine must be transported to hospital immediately for evaluation and observation.

EAIs are available in two dosages (0.15 and 0.3 mg) and prescribed according to weight. The 0.3 mg dosage is indicated for individuals ≥30 kg and 0.15 mg dosage for those 15–30 kg.Citation26,Citation27 Both the American Academy of Pediatrics and Canadian Pediatric Society recommend switching most children from 0.15 to 0.30 mg when they reach a body weight of >25 kg.Citation28,Citation29

EAI devices should be stored avoiding temperature extremes and replaced before the expiration date. In a recent study of EpiPens, it was shown that although there was a gradual decline in concentration over time, >80% of their labeled concentration was retained 50 months after the expiration dates. The authors concluded that the expired EpiPens would likely still provide a beneficial pharmacologic response.Citation30

A significant number of states and Canadian provinces have allowed schools to stock EAIs and train school staff on when to use and how to use EAIs.Citation31,Citation32 In a retrospective study of students (n=6,418,039) attending New York City district public schools, a total of 337 EAI administrations were reported between 2008 and 2013, highlighting an increasing incidence of 1.3 EAI administrations per year (from 3.7/100,000 students in 2008–2009 to 10.1/100,000 students in 2012–2013). A total of 42% of students were administered an EAI due to food-related anaphylaxis (84% PN allergy), and 58% of students treated for anaphylaxis were without a documented allergy. Treatment in these schools most commonly (52%) relied on stock supply of nonstudent-specific EAIs.Citation33 The most frequent cause of anaphylaxis in this study was found to be food. This emphasizes the importance of stock epinephrine in the management of anaphylaxis in the school setting and potentially in other high traffic public places.

The proportion of total students who provided documentation of physician-diagnosed food allergy increased significantly from 0.39% in 2007–2008 to 1.43% in 2012–2013 (P<0.001), as did the proportion of total students with a physician-prescribed EAI, which also increased significantly over the years of the study from 0.26% in 2007–2008 to 0.74% in 2012–2013 (P<0.001).Citation33

Recent findings from a global survey on food allergy revealed that 29% of respondents experienced an allergic reaction but did not administer an EAI for reasons ranging from not thinking the reaction was severe enough to fear of using it.Citation34 This emphasizes the importance of educating patients and their caregivers on avoidance strategies, taking into consideration relevant triggers, age, activity, occupation, hobbies, residential conditions, access to medical care, patient’s anxiety, and the appropriate use of EAIs. All patients at risk of anaphylaxis must always carry an EAI and wear medical identification (i.e., MedicAlert bracelet/necklace).Citation35 An anaphylaxis action plan outlining the recognition and treatment of an anaphylactic reaction as well as the trigger allergen should be developed and made available to the appropriate people (e.g., caregivers, daycare providers, teachers, employers).

Since food avoidance still plays a significant role in food allergy management, a well-balanced elimination diet will keep an individual free of symptoms while maintaining nutritional status. An exception to strict avoidance is CM and egg allergy. Previous studies have shown that the majority of CM-allergic (74%) and egg-allergic (71%) children can tolerate baked milk and baked egg, respectively, which increases the rate of oral tolerance to these food items.Citation36,Citation37

Immunotherapy and desensitization

Food allergy research as well as recent media attention has focused on food desensitization using immunotherapy as a means of food allergy treatment. With immunotherapy, the aim is to first achieve desensitization (temporary) with the ultimate goal being tolerance (permanent) to the allergen. Oral, epicutaneous, and sublingual routes of food desensitization administration have continued to be examined as potential treatments and are primarily available through research protocols as there are currently no approved products for desensitization in the USA and Canada.

Oral immunotherapy (OIT)

In most OIT protocols, food is gradually introduced under medical supervision, with increases in the food dose occurring every 2 weeks. This is continued until a predefined maintenance dose is reached, which is then continued for months to years to maintain desensitization. With the exception of the biweekly dose escalations, daily dosing is done at home. Efficacy is determined by an OFC to the food in question. While multiple randomized control trials have confirmed that OIT is often effective for inducing desensitization (temporary unresponsiveness) and increasing thresholds to various food allergens, tolerance (sustained unresponsiveness) has not generally been achieved. The rate of successful desensitization reported in studies ranges from 35% to 100% (intention to treat) and varies based on the patient’s age, food, chosen food dose, differences in OIT protocols used, and which outcomes were measured (e.g., primary outcome on OFC).Citation38 In a randomized, placebo-controlled trial, Vickery et alCitation39 investigated the efficacy of peanut OIT in young children aged 9–36 months using a low-dose (300 mg/day peanut protein) and high-dose (3,000 mg/day) OIT. They demonstrated that overall 78% of patients achieved sustained unresponsiveness (defined as the ability to consume 5 g of peanut protein without dose-limiting symptoms during an exit double-blind, placebo-controlled food challenge [DBPCFC]) to peanut 4 weeks after stopping OIT and reintroduced peanut into the diet.Citation39 Although this is the highest rate reported to date, patients should be aware that this is still not synonymous with cure, given the short duration of follow-up. Study authors suggest that allergic responses may be more easily modified in young children, but ongoing studies are required to strengthen this hypothesis. There were no treatment-related, severe adverse events (AEs), hospitalizations, or deaths. A total of 85% of the subjects experienced AEs (rash, skin, sneezing/congestion, hives, rash, GI symptoms) that resolved without treatment or with oral antihistamines only (47%). A total of 10 subjects withdrew from the study due to AEs. Epinephrine was not administered during dose-escalation visits but was used once at home dosing.

It has also been observed that cofactors (exercise, infection, etc.) can influence the risk of acute AEs with oral food desensitization, an important consideration in ensuring safety and efficacy when carrying out such therapies.Citation38 OIT studies have reported improved quality of life and less anxiety for those who have completed this process.Citation38

There are currently no approved OIT therapies; however, recent findings of the Peanut AR101 (Aimmune Therapeutics, Brisbane CA, USA) Phase II clinical trial of 55 peanut allergic subjects (4–26 years old) concluded that AR101 (n=29) significantly reduced symptom severity during exit DBP-CFCs and modulated peanut-specific cellular and humoral immune responses versus placebo (n=26). GI symptoms were the most common treatment-related AEs, with six AR101 subjects withdrawing (patient dose ranged between 6 and 80 mg during the escalation phase), four subjects due to recurrent GI AEs.Citation40

Epicutaneous immunotherapy

In epicutaneous immunotherapy, the food is contained in a patch, which is applied to the skin. A randomized double-blind, placebo controlled trial compared two doses of Viaskin Peanut 100 μg (n=24) and Viaskin Peanut 25 μg (n=25) versus placebo (n=25) in children and young adults with peanut allergy (aged 4–25 years; physician-diagnosed peanut allergy or convincing clinical history of peanut allergy, positive SPT wheal size ≥3 mm, or peanut-specific IgE level >0.35). The primary end point was the proportion of participants with a successful outcome after 52 weeks of blinded treatment. Treatment success was defined as either passing a double-blind, placebo-controlled OFC with 5,044 mg of peanut protein at week 52 or by a 10-fold or greater increase in the successfully consumed dose (SCD) of peanut protein compared with the baseline OFC. The results revealed that treatment success was achieved in 12% of placebo-treated participants, 46% of VP100 participants (P=0.005), and 48% of VP250 participants (P=0.003). It was also noted that the highest responses were in children 11 years old or younger.Citation41 In the extension study that included 18 children (6–11 years) treated with 250 μg PN patches for 3 years, there was a trend toward better treatment responses (83.3%) with long-term therapy.Citation42 The adherence rate in these studies was observed to be >95%. In addition, no serious AEs or epinephrine use was reported. Most AEs were mild to moderate, related to the application site, and decreased in both severity and frequency over time.

Sublingual immunotherapy (SLIT)

Desensitization by SLIT utilizes dissolvable tablets or liquid allergen extracts that are placed under the tongue daily. SLIT uses lower doses than OIT and is associated with less AEs, but is generally not as effective.Citation38

Food allergy prevention

Early introduction of food

There have been a number of studies centered on food allergy prevention. Infants with a first-degree relative with a history of allergic disease (allergic rhinitis, asthma, eczema, or food allergy) is at a greater risk of developing food allergy.Citation43

A number of observational studies have suggested that the early and regular consumption of PN, egg, or CM may prevent the development of food allergy.Citation44Citation46 The Learning Early About Peanut (LEAP) trial, a landmark RCT, showed that in high-risk infants (defined as those with severe eczema and/or egg allergy), early introduction of PN between 4 and 11 months of age resulted in a significant reduction in PN allergy. The relative risk reduction was 81% at 5 years of age.Citation47 The Persistence of Oral Tolerance to Peanut (LEAP-On) follow-up study investigated whether the rate of PN allergy in participants who had consumed PN in the primary trial would remain low after 12 months of PN avoidance.Citation48 It showed that the benefits of early PN introduction persisted after a 12-month period of PN avoidance. Based on these findings, the American Academy of Pediatrics has endorsed the updated guidelines regarding high-risk infants (severe eczema and/or egg allergy) and have recommended early introduction of PN between 4 and 6 months of age, with PN IgE testing prior to introduction. In these high-risk infants, if a serum-specific IgE is used to screen and is positive (PN sIgE ≥0.35 kU/L), referral to an allergy specialist for PN SPT and possible supervised feeding are advised. If SPTs are used to screen, results of 0–2 mm have a 95% NPV and home or office introduction is recommended. A 3–7 mm positive skin test has a moderate to high risk and supervised office introduction or graded oral challenge is recommended. Finally, if the SPT is >8 mm, they are likely allergic and should be referred to an allergy specialist. Those at a lower risk (mild to moderate eczema) are recommended to introduce PN at ~6 months taking into account family/cultural preferences. In addition, low-risk (no eczema or food allergy) infants should introduce PN with other solids according to family/cultural preferences.Citation49

Application of these findings remains uncertain as there is no universal agreement on the definition of high-risk infants.Citation50 It is also not clear if these positive outcomes can be generalized to the general population who are not necessarily at high risk.Citation51

The Enquiring about Tolerance (EAT) trial examined whether early introduction of six allergenic food items (PN, egg, CM, sesame, whitefish, and wheat) in exclusively breastfed infants would reduce the prevalence of food allergy by the age of 3 years. In the treatment group, food items were introduced at 3 months of age and continued until 1 year when they were compared to infants who were exclusively breastfed for 6 months (standard introduction group).Citation52 The intention-to-treat analysis revealed a 20% reduction in the prevalence of food allergy in the early introduction group, not statistically significant, but likely related the high rate of nonadherence to the dietary protocol; the per protocol analysis showed a significant difference.

The Hen’s Egg Allergy Prevention (HEAP) study (randomized, placebo-controlled trial) evaluated the efficacy and safety of early hen’s egg introduction at age 4–6 months to prevent hen’s egg allergy in the general population. Of 406 children screened, 383 non-sensitized infants were randomized to receive either verum (egg white powder) or placebo (rice powder). The study in contrast found no evidence that consumption of hen’s egg starting at 4–6 months of age prevented hen’s egg sensitization or allergy.Citation53

Eczema prevention

A personal history of eczema is one of the strongest risk factors for food allergy. In a study by Martin et al, one in five infants with eczema had challenge-confirmed allergy to egg white, PN, or sesame by 12 months of age, compared with only one in 25 infants without eczema. In addition, those with earlier age of onset eczema (first 3 months of life) and increasing severity of eczema (based on treatment required for control) were more likely to develop a food allergy.Citation54

Skin barrier dysfunction is a feature of eczema and is thought to play an important role in allergic sensitization and subsequent progression to food allergy and other allergic disease.Citation55,Citation56 Therefore, prevention of eczema in early life may prevent development of future food allergy and other allergic diseases. One of the primary targets for eczema prevention is improving skin barrier integrity through regular application of a moisturizing cream in infants. An RCT supported the efficacy of this intervention for reducing eczema with significant relative risk reductions ranging from 32% to 50%. However, it is yet to be determined whether prevention of eczema in early life will subsequently prevent allergic sensitization and food allergy.Citation57,Citation58

Summary

Anaphylaxis is an acute and potentially life-threatening allergic reaction. There are a variety of causes; however, food allergy continues to be the leading cause of anaphylaxis and the predominant cause in children. Early recognition and subsequent treatment with epinephrine are critical. Although current management still advises strict avoidance of some foods, new advances in treatment are on the horizon, most notably in the area of PN desensitization. New recommendations for primary prevention of PN and possibly other food allergens will hopefully disrupt the rising prevalence of this important clinical problem.

Study limitations

The literature review did not limit our search to study designs engineered to assess the best quality of evidence. Our broad objective was to highlight current evidence on food allergy and anaphylaxis. In addition, we did not address potential sources of variability between the studies by conducting quality assessment and critical appraisal.

Acknowledgments

The authors did not receive compensation nor was the content of the article influenced in any way. Adamis Pharmaceuticals paid publication fees for the articles in this special issue on anaphylaxis.

Disclosure

SW is an advisory board member for Pfizer Canada and serves as a medical advisor to Food Allergy Canada. The authors report no other conflicts of interest in this work.

References

  • SampsonHAMunoz-FurlonACampbellRLSecond symposium on the definition and management of anaphylaxis: summary report – second national institute of allergy and infectious disease/food allergy and anaphylaxis network symposiumJ Allergy Clin Immunol2006117239139716461139
  • LoVerdeDOnyinyeIIEginliAKrishnaswamyGAnaphylaxisChest2017153252854328800865
  • SimonsFERArdussoLRFBiloBWorld Allergy OrganizationWorld allergy organization guidelines for the assessment and management of anaphylaxisWorld Allergy Organ J20114133723268454
  • LeeSHessEPLohseCGilaniWChamberlainAMCampbellRLTrends, characteristics, and incidence of anaphylaxis in 2001-2010: a population-based studyJ Allergy Clin Immunol2017139118218827378753
  • LiebermanPNicklasRAOppenheimerJThe diagnosis and management of anaphylaxis practice parameter: 2010 updateJ Allergy Clin Immunol2010126347748020692689
  • Gonzalez-EstradaASilversSKKleinAZellKWangXFLangDMEpidemiology of anaphylaxis at a tertiary care center: a report of 730 casesAnn Allergy Asthma Immunol20171181808528007089
  • SollerLShoshanBMHarringtonDWPrevalence and predictors of food allergy in Canada: a focus on vulnerable populationsJ Allergy Clin Immunol Pract201531424925577617
  • AckerWWPlasekJMBlumenthalKGPrevalence of food allergies and intolerances documented in electronic health recordsJ Allergy Clin Immunol201714061587159128577971
  • LeicklyFEKloepferKMSlavenJEVitalpurGPeanut allergy: an epidemiologic analysis of a large databaseJ Pediatr2018192223228.e129246346
  • O’KeefeAClarkeASt PierreYThe risk of recurrent anaphylaxisJ Pediatr201718021722127743592
  • Muñoz-CanoRPascalMAraujoGMechanisms, cofactors, and augmenting factors involving in anaphylaxisFront Immunol20178119329018449
  • SimonsFEREbisawaMSanchez-BorgesM2015 update of the evidence base: world allergy organization anaphylaxis guidelinesWorld Allergy Organ J201583211625709746
  • SichererSHSampsonHAFood allergyJ Allergy Clin Immunol20101252 suppl 2S116S12520042231
  • LeeSBellolioMFHessEPErwinPMuradMHCampbellRLTime of onset and predictors of biphasic anaphylactic reactions: a systematic review and meta-analysisJ Allergy Clin Immunol201533408416 e1–2
  • LiebermanPNicklasRARandolphCAnaphylaxis – a practice parameter updateAnn Allergy Asthma Immunol2015115534138426505932
  • SimonsFERAnaphylaxisJ Allergy Clin Immunol20101252163181
  • HeinzerlingLMariABergmannKCThe skin prick test – European standardsClin Transl Allergy201331323369181
  • GriffithsRLMEl-ShanawanyTJollesSRAComparison of the performance of skin prick, immunoCAP and ISAC tests in the diagnosis of patients with allergyInt Arch Allergy Immunol2017172421522328456812
  • FishbeinABMakhijaMMPongracicJAAnaphylaxis to foodImmunol Allergy Clin N Am2015352231245
  • KlemansRJvan Os-MedendorpHBlankestijnMBruijnzeel-KoomenCAKnolEFKnulstACDiagnostic accuracy of specific IgE to components in diagnosing peanut allergy: a systematic reviewClin Exp Allergy201545472073025226880
  • TuanoKDavisCMUtility of component-resolved diagnostics in food allergyCurr Allergy Asthma Rep20151563226141579
  • AkueteKGuffeyDIsraelsenRBMulticenter prevalence of anaphylaxis in clinic-based oral food challengesAnn Allergy Asthma Immunol20171194339348.e128890356
  • ChanJCPetersRLKoplinJJFood challenge and community-reported reaction profiles in food-allergic children aged 1 and 4 years: a population-based studyJ Allergy Clin Immunol Pract201752398409.e328283159
  • YanagidaNSatoSAsaumiTOguraKEbisawaMRisk factors for severe reactions during double-blind placebo-controlled food challengesInt Arch Allergy Immunol2017172317318228380495
  • SheikhASimonsFEBarbourVWorthAAdrenaline auto-injectors for the treatment of anaphylaxis with and without cardiovascular collapse in the communityCochrane Database Syst Rev20128CD00893522895980
  • EpiPen® (Sterile epinephrine injection) USP Unidose 0.3 mg epinephrine auto-injector [Prescribing Information]CA, USADey Pharma, L.P. Napa2012
  • EpiPen® Jr. (Sterile epinephrine injection) USP Unidose 0.15 mg epinephrine auto-injector [Prescribing Information]CA, USADey Pharma, L.P. Napa2012
  • SichererSHSimonsFERSection on Allergy and Immunology. Epinephrine for first-aid management of anaphylaxisPediatrics20171393e2016400628193791
  • ChengAEmergency treatment of anaphylaxis in infants and childrenPaediatr Child Health2011161354022211074
  • CantrellFLCantrellPWenAGeronaREpinephrine concentrations in EpiPens after the expiration dateAnn Intern Med20171661291891928492859
  • HogueSLGossDHollisKSilviaSWhiteMVTraining and administration of epinephrine auto-injectors for anaphylaxis treatment in US schools: results from the EpiPen4Schools pilot surveyJ Asthma Allergy2016910911527382317
  • WhiteMVHogueSLBennettMEEpiPen4Schools pilot survey: occurrence of anaphylaxis, triggers, and epinephrine administration in a U.S. school settingAllergy Asthma Proc201536430631225898241
  • FeuilleELawrenceCVolelCSichererSHWangJTime trends in food allergy diagnoses, epinephrine orders, and epinephrine administrations in New York City schoolsJ Pediatr2017190939929144278
  • WasermanSGlobal review of epinephrine availability and anaphylaxis management practices amongst patient organization countriesAbstracts from the European Academy of Allergy and Clinical Immunology CongressJune 17–21; 2017Helsinki, Finland72S103216217
  • WasermanSChadZFrancoeurMJManagement of anaphylaxis in primary care: Canadian expert consensus recommendationsAllergy20106591082109220584005
  • LeonardSASampsonHASichererSHDietary baked egg accelerates resolution of egg allergy in childrenJ Allergy Clin Immunol2012130247348022846751
  • KimJSNowak-WęgrzynASichererSHNooneSMoshierELSampsonHADietary baked milk accelerates the resolution of cow’s milk allergy in childrenJ Allergy Clin Immunol2011128112513121601913
  • GernezYNowak-WęgrzynAImmunotherapy for food allergy: are we there yet?J Allergy Clin Immunol Pract20175225027228283151
  • VickeryBPBerglundJPBurkCMEarly oral immunotherapy in peanut-allergic preschool children is safe and highly effectiveJ Allergy Clin Immunol20171391173181.e827522159
  • BirdJASpergelJMJonesSMARC001 Study GroupEfficacy and safety of AR101 in oral immunotherapy for peanut allergy: results of ARC001, a randomized, double-blind, placebo-controlled phase 2 clinical trialJ Allergy Clin Immunol Pract201862476485.e329092786
  • JonesSMSichererSHBurksAWConsortium of Food Allergy ResearchEpicutaneous immunotherapy for the treatment of peanut allergy in children and young adultsJ Allergy Clin Immunol2017139412421252.e928091362
  • ShrefflerWGEfficacy and safety of long-term epicutaneous immunotherapy (EPIT) treatment of peanut allergy with Viaskin® peanut: results of the two-year extension of the VIPES phase IIb clinical trialPresented at: Annual Meeting of the American Academy of Allergy, Asthma & ImmunologyMarch 5; 2017Atlanta, GA
  • BoyceJAAssa’adABurksAWGuidelines for the diagnosis and management of food allergy in the United States: report of the NIAID-sponsored expert panelJ Allergy Clin Immunol20101266 supplS1S5821134576
  • Du ToitGKatzYSasieniPEarly consumption of peanuts in infancy is associated with a low prevalence of peanut allergyJ Allergy Clin Immunol2008122598499119000582
  • KoplinJJOsborneNJWakeMCan early introduction of egg prevent egg allergy in infants? A population-based studyJ Allergy Clin Immunol2010126480781320920771
  • KatzYRajuanNGoldbergMREarly exposure to cow’s milk protein is protective against IgE-mediated cow’s milk protein allergyJ Allergy Clin Immunol201012617782.e120541249
  • Du ToitGRobertsGSayrePHRandomized trial of peanut consumption in infants at risk for peanut allergyN Engl J Med2015372980381325705822
  • Du ToitGSayrePHRobertsGEffect of avoidance on peanut allergy after early peanut consumptionN Engl J Med2016374151435144326942922
  • TogiasACooperSFAcebalMLAddendum guidelines for the prevention of peanut allergy in the United States: report of the national institute of allergy and infectious diseases-sponsored expert panelAnn Allergy Asthma Immunol2017118216617328065802
  • HoffmanBMorenoLGerberLD’AngeloEAbramsonEWhat pediatricians are advising on infant peanut introductionAnn Allergy Asthma Immunol20171195S10
  • FleischerDMLife after LEAP: how to implement advice on introducing peanuts in early infancyJ Paediatr Child Health201753S139
  • PerkinMRLoganKTsengARandomized trial of introduction of allergenic foods in breast-fed infantsN Engl J Med2016374181733174326943128
  • BellachJSchwarzVAhrensBRandomized placebo-controlled trial of hen’s egg consumption for primary prevention in infantsJ Allergy Clin Immunol2017139515911599.e227523961
  • MartinPEEckertJKKoplinJJHealthNuts Study InvestigatorsWhich infants with eczema are at risk of food allergy? Results from a population-based cohortClin Exp Allergy201545125526425210971
  • LackGEpidemiologic risks for food allergyJ Allergy Clin Immunol200812161331133618539191
  • CzarnowickiTKruegerJGGuttman-YasskyENovel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic marchJ Allergy Clin Immunol201713961723173428583445
  • HorimukaiKMoritaKNaritaMApplication of moisturizer to neonates prevents development of atopic dermatitisJ Allergy Clin Immunol20141344824830.e625282564
  • SimpsonELChalmersJRHanifinJMEmollient enhancement of the skin barrier from birth offers effective atopic dermatitis preventionJ Allergy Clin Immunol2014134481882325282563